CAR-T Cell Therapy
Hematology
Kuanzia
$47,000
Hadi $200,000 kulingana na kituo
Muda wa kawaida
20–50 days
Ikiwemo uchunguzi wa kabla ya upasuaji
Hospitali washirika
0
Zimechunguzwa kwa data ya matokeo na vyeti
Muhtasari
CAR-T (Chimeric Antigen Receptor T-cell) therapy is a revolutionary form of personalised cancer immunotherapy in which a patient's own T-cells are genetically engineered to identify and destroy cancer cells with precision. Approved for certain blood cancers — including relapsed or refractory B-cell lymphomas, acute lymphoblastic leukaemia (ALL), and multiple myeloma — CAR-T has achieved remission in patients who failed all prior therapies. China is a world leader in CAR-T innovation with domestically approved products (Relma-cel, Yescarta/Fosun Kite) at a fraction of US costs. India offers the homegrown NexCAR19 product at around $50,000 — one-tenth of the US price — through JCI-accredited centres including Christian Medical College Vellore.
Kesi yako inalinganishwa na kituo kwa msingi wa data ya matokeo ya kitabibu, si matangazo. Tunaratibu kila hatua — kuanzia uchunguzi wa kabla ya upasuaji hadi ufuatiliaji wa baada ya matibabu — pamoja na mratibu maalum wa huduma.
Kinachojumuishwa
CAR-T Cell Therapy
Imeratibiwa kuanzia
au tutumie ujumbe kwenye WhatsApp
Hakuna ahadi inayohitajika. Data yako kamwe haishirikiwi na wahusika wengine.
Ulinganisho wa gharama duniani — CAR-T Cell Therapy
Wastani wa gharama zilizoratibiwa katika vituo vyetu washirika. Bei ya mwisho inategemea uzito wa kitabibu na hospitali iliyochaguliwa.
| Nchi | Wastani wa gharama | ikilinganishwa na ya bei nafuu zaidi |
|---|---|---|
🇮🇳 India New Delhi · Chennai · Bengaluru · Hyderabad · Mumbai · Kochi | $65,000 | —chevron_right |
🇨🇳 China Shanghai · Beijing · Hainan (Boao) | $150,000 | +131%chevron_right |
Gharama ni za makadirio na zinapitiwa kila robo mwaka. Omba makadirio ya kibinafsi kwa kesi yako mahususi.
Maswali yanayoulizwa mara kwa mara
CAR-T is currently approved for relapsed or refractory large B-cell lymphoma (including DLBCL), follicular lymphoma, mantle cell lymphoma, B-cell acute lymphoblastic leukaemia (ALL), and multiple myeloma after prior lines of therapy. Eligibility depends on your specific cancer subtype, prior treatment history, molecular markers (e.g., CD19, BCMA expression), and performance status. Our partner centres will review your pathology reports, treatment history, and imaging to determine candidacy before you travel.
Hakuna ada. Hakuna ahadi.
Muongozo wetu ni wa bure kabisa
Tunalipwa na hospitali zetu washirika — kamwe na wagonjwa. Unapata ulinganishaji huru wa kitabibu, uwazi wa gharama, na uratibu kamili bila gharama kwako.